ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,067.69
0.19%
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs Yen
155.675
0.00%
Brent Oil
83.76
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Evaxion Biotech AS (EVAX)

  7. Evaxion Biotech AS (EVAX) ニュース

EVAX

Evaxion Biotech AS (EVAX)

Evaxion Biotech AS
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:EVAX
日付受信時刻ニュースソース見出しコード企業名
2024/05/1106 : 29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/05/1106 : 00GlobeNewswire Inc.Evaxion Receives Nasdaq NotificationNASDAQ:EVAXEvaxion Biotech AS
2024/05/0706 : 01Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:EVAXEvaxion Biotech AS
2024/04/1721 : 00GlobeNewswire Inc.Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01NASDAQ:EVAXEvaxion Biotech AS
2024/04/0220 : 00GlobeNewswire Inc.Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus InfectionNASDAQ:EVAXEvaxion Biotech AS
2024/03/2720 : 30GlobeNewswire Inc.Evaxion Announces Business Update and Full Year 2023 Financial ResultsNASDAQ:EVAXEvaxion Biotech AS
2024/03/1920 : 30GlobeNewswire Inc.Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ PlatformNASDAQ:EVAXEvaxion Biotech AS
2024/02/2921 : 35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/02/2921 : 30GlobeNewswire Inc.Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology InnovationsNASDAQ:EVAXEvaxion Biotech AS
2024/02/2021 : 32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/02/2021 : 30GlobeNewswire Inc.Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDNASDAQ:EVAXEvaxion Biotech AS
2024/02/0806 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/02/0722 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/02/0722 : 30GlobeNewswire Inc.Evaxion Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:EVAXEvaxion Biotech AS
2024/02/0622 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/02/0622 : 30GlobeNewswire Inc.Evaxion Announces Closing of $15 Million Public OfferingNASDAQ:EVAXEvaxion Biotech AS
2024/02/0523 : 09Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:EVAXEvaxion Biotech AS
2024/02/0521 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/02/0214 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVAXEvaxion Biotech AS
2024/02/0123 : 20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/02/0123 : 20GlobeNewswire Inc.Evaxion Biotech Announces Pricing of $15 Million Public OfferingNASDAQ:EVAXEvaxion Biotech AS
2024/02/0107 : 10Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:EVAXEvaxion Biotech AS
2024/01/3123 : 26Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:EVAXEvaxion Biotech AS
2024/01/3105 : 16Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:EVAXEvaxion Biotech AS
2024/01/2706 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/01/2504 : 11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/01/2422 : 30GlobeNewswire Inc.Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered TargetsNASDAQ:EVAXEvaxion Biotech AS
2024/01/2306 : 45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
2024/01/2306 : 30GlobeNewswire Inc.Evaxion Announces Completion of ADS Ratio ChangeNASDAQ:EVAXEvaxion Biotech AS
2024/01/1307 : 17Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:EVAXEvaxion Biotech AS
 Showing the most relevant articles for your search:NASDAQ:EVAX

最近閲覧した銘柄

EU
CAHAX
Credit Agricole home Loa...
USOTC
OCLDF
Orica (PK)
LSE
0EV1
Carnival
LATK
RITBTC
Uberstate Real Estate Investment
COIN
SECUSD
COIN
GRAFTGBP
GRAF SOUND T
TSX
FGOV
Franklin Canadian Govern...
LSE
14H3
BIT
SMON5L
Societe Generale Effekten
HITB
BICOUSDT
Biconomy Token
EU
Q673S
Q673S
USOTC
IPDQF
Impedined (PK)
NASDAQ
RDHL
Redhill Biopharma
BIT
S28711
Societe Generale Effekten
TSX
PYF.B
Purpose Premium Yield
NYSE
APO.PRA
Apollo Global Management LLC
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有